Varlilumab

DB11930InvestigationalProtein Based Therapies

Varlilumab has been used in trials studying the treatment of MELANOMA, Skin Ulcer, Burkett's Lymphoma, Mantle cell lymphoma, and Any T-cell Malignancy, among others.

Mechanism: Pharmacologically active on CD27 antigen
Curator reviewed
Code names: CDX-1127

Resolves to

Compound

UNII0125DUV5XCCAS1393344-72-3

Targets

P26842CD27

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

381Drug interactionsStructured to mechanism, not free text

15Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Varlilumab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account